Химиотерапия: открытый доступ
Открытый доступ
ISSN: 2167-7700
ISSN: 2167-7700
Weiwei Tang, Jian Zhou, Handong Sun, Yun Hu, Jian Zhou, Yiwei Yao, Qian Wang, Hongyong Cao and Hanjin Wang
Enhancer of zeste homolog2 (EZH2) is a polycomb group protein, playing a key role in epigenetic chromatin modifying, cell-cycle regulating, and has been reported associated with a variety of malignancies. Published research on EZH2 gene polymorphism and cancer risk are inconsistent, therefore, this study aimed to evaluate the association between EZH2 gene polymorphism and several types of cancer risks. Computerized literature search was carried out in the PubMed, Web of Science, EMBASE and China National Knowledge Infrastructure (CNKI) before the date of July 20, 2017. Each gene was estimated by odds ratios(ORs) and 95% confidence intervals (CIs) and I2 value was used to assess heterogeneity. Overall analysis were carried out with RevMan5.3 software. The result showed the individuals carrying at least one T allele at EZH2 rs3757441 had a 1.52 fold higher risk of developing cancer and those carrying at least one C allele at EZH2 rs2302427 had a 1.68 fold higher risk of developing cancer. In particular , EZH2 rs6950683 polymorphism and cancer risk was significantly observed in each comparison model. In conclusion, our meta-analysis indicated that the EZH2 polymorphism was associated with risks of developing carcinomas and larger sample sizes of studies are suggested performed to further validate our results.